111 / 1631
Chimeric Antigen Receptor T Cells for Sustained Remissions in
Leukemia Shannon L. Maude et al NEJM . 2014 ; 371(16): 1507–151
• Sustained remission was achieved with a 6-month EFS of 67% and an overall survival
rate of 78%.
• At 6 months,
– probability of persistence of CTL019 was 68%
– probability that a patient would have relapse-free B-cell aplasia was 73%.
• All the patients had the cytokine-release syndrome, Severe cytokine-release syndrome
developed in 27% of the patients, (associated with a higher disease burden before
infusion and was effectively treated with the anti–interleukin-6 receptor antibody
tocilizumab.)
• Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating
relapsed and refractory ALL. CTL019 was associated with a high remission rate, even
among patients for whom stem-cell transplantation had failed, and durable remissions
up to 24 months were observed